Cosmo Pharmaceuticals Appoints Chief Strategy Officer
Cosmo Pharmaceuticals (SIX: COPN, FSE: C43) has announced the appointment of Dominika Spilarova as Chief Strategy Officer, effective January 10, 2025. This newly created position will report directly to the CEO. Spilarova brings over 15 years of experience in Life Sciences and management consulting, having previously worked with PwC and running her own Life Sciences consulting business. She has a track record of developing strategies that have impacted businesses with revenues ranging from $26 million to $19.5 billion.
In addition to her CSO role, Spilarova will serve as acting Chief of Staff for the executive leadership team until a permanent appointment is made. The appointment comes as Cosmo reports a strong close for Full Year 2024, with the company focusing on strategy-led growth and innovation.
Cosmo Pharmaceuticals (SIX: COPN, FSE: C43) ha annunciato la nomina di Dominika Spilarova come Chief Strategy Officer, a partire dal 10 gennaio 2025. Questa posizione, appena creata, riporterà direttamente al CEO. Spilarova porta con sé oltre 15 anni di esperienza nei Life Sciences e nella consulenza manageriale, avendo precedentemente lavorato con PwC e gestito una propria attività di consulenza nel settore Life Sciences. Ha un comprovato track record nello sviluppo di strategie che hanno avuto impatto su aziende con ricavi compresi tra 26 milioni e 19,5 miliardi di dollari.
Oltre al suo ruolo di CSO, Spilarova servirà come Chief of Staff ad interim per il team di leadership esecutiva fino a quando non verrà effettuata una nomina permanente. La nomina arriva mentre Cosmo riporta una chiusura forte per l'anno intero 2024, con l'azienda che si concentra su una crescita e un'innovazione guidate dalla strategia.
Cosmo Pharmaceuticals (SIX: COPN, FSE: C43) ha anunciado el nombramiento de Dominika Spilarova como Directora de Estrategia, a partir del 10 de enero de 2025. Esta posición, recién creada, reportará directamente al CEO. Spilarova aporta más de 15 años de experiencia en Ciencias de la Vida y consultoría de gestión, habiendo trabajado previamente con PwC y dirigiendo su propio negocio de consultoría en Ciencias de la Vida. Tiene un historial comprobado en el desarrollo de estrategias que han impactado a empresas con ingresos que van desde $26 millones hasta $19.5 mil millones.
Además de su rol como CSO, Spilarova asumirá el cargo de Jefa de Personal interina para el equipo de liderazgo ejecutivo hasta que se realice un nombramiento permanente. La designación llega mientras Cosmo informa un cierre sólido para el Año Completo 2024, enfocándose en un crecimiento e innovación impulsados por la estrategia.
Cosmo Pharmaceuticals (SIX: COPN, FSE: C43)는 Dominika Spilarova를 2025년 1월 10일부로 최고 전략 책임자로 임명한다고 발표했습니다. 새로 생긴 이 직위는 CEO에게 직접 보고합니다. Spilarova는 PWCs에서 근무하고 생명과학 컨설팅 사업을 운영한 경험이 있는 생명과학 및 관리 컨설팅에서 15년 이상의 경력을 보유하고 있습니다. 그녀는 2천6백만 달러에서 1천9백50억 달러에 이르는 수익을 가진 기업에 영향을 미치는 전략 개발의 실적을 가지고 있습니다.
CSO 역할 외에도 Spilarova는 영구적인 임명이 이루어질 때까지 집행 리더십 팀을 위한 직무 대행 책임자로 활동할 것입니다. Cosmo는 2024년 전체 연도 강력한 마감을 보고하며, 전략 주도 성장 및 혁신에 중점을 두고 있습니다.
Cosmo Pharmaceuticals (SIX: COPN, FSE: C43) a annoncé la nomination de Dominika Spilarova au poste de Directrice de la Stratégie, à compter du 10 janvier 2025. Ce poste nouvellement créé rendra compte directement au PDG. Spilarova possède plus de 15 ans d'expérience dans les sciences de la vie et le conseil en management, ayant auparavant travaillé avec PwC et dirigé sa propre entreprise de conseil en sciences de la vie. Elle a un bilan avéré dans le développement de stratégies qui ont eu un impact sur des entreprises avec des revenus allant de 26 millions à 19,5 milliards de dollars.
En plus de son rôle de CSO, Spilarova agira en tant que Chef de Cabinet par intérim pour l'équipe de direction exécutive jusqu'à ce qu'un recrutement permanent soit effectué. La nomination intervient alors que Cosmo annonce une clôture solide pour l'année entière 2024, l'entreprise se concentrant sur une croissance et une innovation axées sur la stratégie.
Cosmo Pharmaceuticals (SIX: COPN, FSE: C43) hat die Ernennung von Dominika Spilarova zur Chief Strategy Officer bekannt gegeben, die am 10. Januar 2025 in Kraft tritt. Diese neu geschaffene Position berichtet direkt an den CEO. Spilarova bringt über 15 Jahre Erfahrung in den Lebenswissenschaften und in der Managementberatung mit, nachdem sie zuvor bei PwC gearbeitet und ihr eigenes Beratungsunternehmen im Bereich Lebenswissenschaften geleitet hat. Sie hat eine nachgewiesene Erfolgsbilanz in der Entwicklung von Strategien, die Unternehmen mit einem Umsatz von 26 Millionen bis 19,5 Milliarden Dollar beeinflusst haben.
Zusätzlich zu ihrer Rolle als CSO wird Spilarova als Interim Chief of Staff für das Führungsteam fungieren, bis eine dauerhafte Ernennung erfolgt. Die Ernennung erfolgt, während Cosmo einen starken Abschluss für das Gesamtjahr 2024 meldet und sich auf wachstums- und innovationsorientierte Strategien konzentriert.
- Creation of new strategic leadership position indicates company's focus on growth
- New CSO brings experience with businesses ranging from $26M to $19.5B in revenue
- Company reports strong close for Full Year 2024
- None.
Dublin, Ireland--(Newsfile Corp. - December 12, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) is pleased to announce the appointment of Dominika Spilarova as its Chief Strategy Officer, effective January 10, 2025. This newly created role within Cosmo’s leadership team highlights the company's focus on strategy-led growth and innovation. She will be reporting to the CEO.
Dominika brings over 15 years of diverse experience in and outside of the Life Sciences industry, as well as a background in management consulting with PwC and independent consulting globally. Throughout her career, she has successfully developed and executed innovative strategies that have driven measurable results, including new product offerings, revenue growth, and operational efficiencies. Her contributions have positively impacted businesses ranging from
Dominika has extensive experience in building and leading high-performing teams, ranging from small agile teams to teams of over 50 people. Her coaching qualification further enables her to help employees unlock their potential, both individually and as a group. She remains dedicated to advancing women in the workplace through her not-for-profit coaching work and as a member of the “Forbes Forum for Female Leaders”.
Dominika’s deep understanding of the end-to-end value chain in Life Sciences positions her to lead tangible strategy execution across all levels of Cosmo. In addition to her new role as Chief Strategy Officer, she will also serve as acting Chief of Staff for the executive leadership team of Cosmo, until a permanent appointment for this position is made in the near term.
Giovanni Di Napoli, CEO of Cosmo, commented:
“As we are executing a strong close for our Full Year 2024, we continue to attract talents at Cosmo. Dominika’s appointment comes at a pivotal time for Cosmo. Her wealth of experience and track record in driving impactful strategies make her the ideal leader to help shape the next phase of our growth. We are building incredible momentum as a company, with a strong pipeline, innovative solutions, and a talented team committed to making a difference in patients’ lives. I am thrilled to welcome Dominika to the Cosmo family, and I’m confident her leadership will further strengthen our ability to achieve our ambitious goals. This new role reflects our focus on the future, ensuring that we continue to evolve and deliver on our commitments to patients, partners, and stakeholders. Dominika’s expertise and passion for leadership will be instrumental in this journey.”
Dominika Spilarova stated:
“It is a privilege to join Cosmo, a company with a remarkable legacy and support the shaping of its bright future. I look forward to collaborating with the exceptional team at Cosmo, as well as our partners and customers, to drive innovation and growth in the service of patients worldwide. I am also deeply committed to continuing my work in supporting women in the workplace and helping to create more opportunities for future leaders. Together, we will continue to address critical health needs with tangible impact.”
About Cosmo
Cosmo Pharmaceuticals N.V. is committed to revolutionizing healthcare and transforming people’s lives by researching and developing innovative products that tackle unfulfilled healthcare demands. As a pharmaceutical company, Cosmo is active in the areas of healthtech/AI, dermatology, gastroenterology and contract manufacturing & development. The current growth drivers, including the state-of-the-art GI Genius™ intelligent endoscopy system that enhances polyp detection rates during colonoscopy and the prescription drug Winlevi® to treat acne are generating substantial revenue streams. The Company’s proprietary MMX® technology enables targeted delivery of active ingredients in the colon and is a cornerstone of its product development. Cosmo also has a robust clinical development pipeline, which includes Breezula® for the treatment of androgenetic alopecia. For the commercialization and distribution of its products, Cosmo collaborates with leading partners worldwide, including Medtronic and Sun Pharma. Founded in 1997, Cosmo is headquartered in Dublin (Ireland) and has offices also in San Diego (USA), and Lainate/Rome/Catania (Italy). The Company currently has approximately 330 employees, all dedicated to making a significant impact in the field of healthcare. For more information, please visit www.cosmopharma.com.
Upcoming Calendar of Events
Baader Swiss Equities Conference, Bad Ragaz January 8 - 10, 2025
J.P. Morgan European Opportunities Forum, London March 11 - 13, 2025
26th Kepler Cheuvreux Swiss Seminar, Zurich March 19 – 20, 2025
For further information, please contact
Hazel Winchester
Head of Investor Relations
Cosmo Pharmaceuticals N.V.
Tel: +353 1 817 03 70
hwinchester@cosmopharma.com
Disclaimer
Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. Cosmo does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements. Therefore, in no case whatsoever will Cosmo and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages.
Attachments
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/233490
FAQ
When will Dominika Spilarova start as Chief Strategy Officer at Cosmo Pharmaceuticals (CMOPF)?
What is the reporting structure for the new CSO position at CMOPF?
What additional role will Spilarova hold at CMOPF besides CSO?
What is the range of business revenues Spilarova has experience with?
How does this appointment align with CMOPF's current business performance?
